Hepatic histological comparison between Acute Self-limiting Hepatitis A and Hepatitis E

Published On: June 21, 2017 | Pages: 041 - 048

Author(s): Kazuyuki Suzuki*, Yoshitoku Tatemichi, Yuichi Yoshida, Yasuhiro Miyamoto, Hidekatsu Kuroda, Akio Miyasaka, Yasuhiro Takikawa, Tomoyuki Masuda, Ichiro Kumagai and Hiroaki Okamoto

Background: Histological findings of the liver in acute liver injury are basically affected by degree of liver damage. However, the differences in liver histology between acute self-limiting hepatitis A (AH-A) and hepatitis E (AH-E) have not yet been clarified. This study aimed to clarify the differences in histological findings of the liver between AH-A and AH-E.

Hepatitis E: New Clinical and Public Health Problem on the Western World?

Published On: March 31, 2017 | Pages: 019 - 022

Author(s): Roberto Focaccia*

Until recently, the occurrence of Hepatitis E in the western hemisphere did not amount to a clinical concern, due to its benign and usually sub-clinical evolution, as opposed to Asia and Africa, where large epidemics with high levels of lethality occur.
Relative and combined Effects of Ethanol and Hepatitis C Virus Infection on Serum Interleukin-17 Levels

Published On: March 20, 2017 | Pages: 013 - 018

Author(s): Emilio González-Reimers*, Candelaria Martín-González, Geraldine Quintero-Platt, Lucía Romero-Acevedo, Onán Pérez-Hernández, Elisa Espelosín-Ortega, María José de-la- Vega-Prieto, Antonieta González-Díaz and Francisco Santolari-Fernández

Background: Interleukin-17 (IL-17) is involved in neutrophil recruitment and may contribute to the progression from fatty liver to steatohepatitis. ...

Liver Specific Serum Micro RNA122 as a Prognostic Marker in Egyptian Patients with Liver Cirrhosis

Published On: January 30, 2017 | Pages: 004 - 009

Author(s): Mona A Amin*, Mai Fawzi, Dina Sabri, Heba Sedrak, Shrouk Mausa and Abdelaziz El-Saadi

Introduction: Recent research has shown that microRNAs (miRNA) are emerging as important regulators of cellular differentiation. The miR-122 accounts for approximately 70% of all miRNAs in the liver so its presence in the serum is highly indicative of liver processes. ...

Vitamin K: A potential Liver Cancer treatment way

Published On: September 26, 2017 | Pages: 049 - 052

Author(s): Sofi a Dahlberg and Ulf Schött*

A review on different vitamin K1-3 effects on hepatocellular cancer and their tumour cell biology mechanism indicate possible synergistic treatment strategies. ...
Farnesoid X Receptor Agonist as a new treatment option for Non-Alcoholic Fatty Liver disease: A Review

Published On: June 12, 2017 | Pages: 029 - 036

Author(s): Sukhpreet Singh and Kusum K Kharbanda*

Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of fatty liver, characterized by the accumulation of fat in the hepatocytes in the absence of alcohol consumption. The spectrum of this disease ranges from steatosis to hepatitis and finally cirrhosis and hepatocellular carcinoma.

Accidentally discovered Portal Vein Thrombosis before Splenectomy due to Hypersplenism - The role of Thrombogenic Genes Polymorphisms

Published On: June 19, 2017 | Pages: 037 - 040

Author(s): Amr Shaaban Hanafy*

Portal vein thrombosis in patients with liver cirrhosis may be due neoplastic growth invading portal vein or due to non-neoplastic causes. The indications for treating PVT in cirrhotic individuals are difficult to be established but at least are of great benefit in acute PVT. Investigating the cause of portal vein thrombosis in cirrhotic patient prepared for splenectomy...

Constipation during Entecavir treatment in Chronic Hepatitis B patients: Two Cases Reports

Published On: May 29, 2017 | Pages: 027 - 028

Author(s): Meng-Lan Wang, Dong-Mei Zhang and En-Qiang Chen*

Entecavir (ETV) is an oral nucleoside analog inhibitor of hepatitis B virus (HBV) DNA polymerase, which is widely used in patients with chronic hepatitis B (CHB). Despite the excellent safety data of this agent, the adverse events of headache,
diarrhea, nausea and vomiting are recorded in the drug instruction of ETV. Here we report two CHB patients with ETV-associate ...

**Sarcoidosis-Lymphoma Syndrome presenting by severe Cholestatic Hepatitis**

Published On: May 18, 2017 | Pages: 023 - 026

Author(s): Omkolsoum M Alhaddad1, Maha M Elsabaawy*, Omar A Shaarawy, Nermin A Ehsan, Doha Maher, Khaled Gmeel, Eman A Rewisha and Imam A Waked

Severe cholestatic hepatitis is an uncommon presentation of either sarcoidosis or Hodgkin lymphoma. Sarcoidosis lymphoma syndrome is a rare disorder with sarcoidosis heralding the onset of lymphoma. Here we report a case of coexisting sarcoidosis-Hodgkin’s lymphoma syndrome presenting with severe cholestatic hepatitis. ...

**The Potential of Liver Fibrosis Indexes/Scores for the Screening of Cryptic Liver Fibrosis in Patients with NASH Risk Factors: A Case Report**

Published On: January 27, 2017 | Pages: 001 - 003

Author(s): Eguiluz M, Andrés-Otero MJ, De-Blas I, Puente-Lanzarote JJ, Lorente-Pérez S, Soria M and Lou-Bonafonte JM*

The unintentional discovery of cirrhosis in a patient with prostate cancer lead us to enquire if some of the indexes/scored designed for the evaluation of liver fibrosis/cirrhosis, in Chronic Hepatitis C patients, could have helped us in the detection of incipient liver fibrosis, and its follow up, in this patient. ...

**Hepatitis E: Diagnostic and Therapeutic Challenges**
Hepatitis E virus (HEV) is a globally important water and foodborne pathogen of acute and chronic hepatitis E [1,2]. HEV infection may be symptomatic or asymptomatic that has affected about one-third of world population with a case fatality rate of 1-2%, including 20-30% of infected pregnant women [3-5].